Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 7/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 6/20 | 0.33 |
| ▸ | RXRG | P48443 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | ESRRG | P62508 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium SCHEMBL7182311 | 0.97 | TP53 (0.35) | TP53THRBSMN1; SMN2RXRBLMNA | |
| SCHEMBL7181221 | 0.85 | KMT2A (0.35) | SMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL7175212 | 0.84 | RXRB (0.38) | RXRBLMNARXRARXRGL3MBTL1 | |
| SCHEMBL7188981 | 0.83 | L3MBTL1 (0.36) | THRBSMN1; SMN2ALDH1A1TDP1ACHE | |
| SCHEMBL7182174 | 0.83 | POLB (0.34) | TP53RXRBALDH1A1RXRARXRG | |
| SCHEMBL7190121 | 0.83 | POLB (0.34) | RXRBRXRARXRGPOLBMAPT | |
| SCHEMBL7180974 | 0.83 | RXRB (0.36) | TP53THRBSMN1; SMN2RXRBLMNA | |
| SCHEMBL7180014 | 0.83 | RXRB (0.39) | TP53THRBSMN1; SMN2RXRBLMNA | |
| Lithium SCHEMBL7181229 | 0.82 | KMT2A (0.35) | SMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| Lithium SCHEMBL7175218 | 0.81 | RXRB (0.38) | RXRBLMNARXRARXRGL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | TP53 3575/4885THRB 2119/4885SMN1; SMN2 2939/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | TP53 3524/4885THRB 2521/4885SMN1; SMN2 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.